| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 24 | 2020 | 302 | 2.250 |
Why?
|
| Cognition | 21 | 2020 | 551 | 1.840 |
Why?
|
| Growth Hormone-Releasing Hormone | 4 | 2018 | 7 | 1.020 |
Why?
|
| Neuropsychological Tests | 22 | 2019 | 363 | 0.930 |
Why?
|
| Insulin | 12 | 2015 | 367 | 0.930 |
Why?
|
| Postmenopause | 7 | 2019 | 427 | 0.910 |
Why?
|
| Exercise | 8 | 2019 | 679 | 0.820 |
Why?
|
| Cognition Disorders | 8 | 2013 | 370 | 0.810 |
Why?
|
| Exercise Therapy | 4 | 2020 | 271 | 0.790 |
Why?
|
| Hormones | 2 | 2013 | 20 | 0.780 |
Why?
|
| Glucose | 4 | 2013 | 184 | 0.750 |
Why?
|
| Insulin Resistance | 7 | 2019 | 469 | 0.730 |
Why?
|
| Aged | 48 | 2019 | 10544 | 0.690 |
Why?
|
| Peptide Fragments | 8 | 2018 | 403 | 0.640 |
Why?
|
| Cacao | 1 | 2019 | 4 | 0.620 |
Why?
|
| Aged, 80 and over | 26 | 2019 | 4034 | 0.610 |
Why?
|
| Estradiol | 3 | 2011 | 121 | 0.600 |
Why?
|
| Double-Blind Method | 16 | 2019 | 525 | 0.600 |
Why?
|
| Hypovolemia | 1 | 2018 | 3 | 0.590 |
Why?
|
| Female | 53 | 2019 | 20271 | 0.590 |
Why?
|
| Phlebotomy | 1 | 2018 | 16 | 0.590 |
Why?
|
| Vitamins | 1 | 2019 | 73 | 0.590 |
Why?
|
| Plant Extracts | 1 | 2019 | 61 | 0.590 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 54 | 0.580 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 36 | 0.580 |
Why?
|
| Hepatectomy | 1 | 2018 | 56 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2019 | 1462 | 0.570 |
Why?
|
| Dietary Supplements | 1 | 2019 | 187 | 0.550 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 5 | 2019 | 54 | 0.540 |
Why?
|
| Brain | 7 | 2017 | 946 | 0.530 |
Why?
|
| Humans | 63 | 2020 | 32814 | 0.530 |
Why?
|
| Male | 46 | 2019 | 19650 | 0.510 |
Why?
|
| Life Style | 6 | 2020 | 407 | 0.490 |
Why?
|
| Memory | 8 | 2018 | 191 | 0.480 |
Why?
|
| Middle Aged | 31 | 2019 | 12133 | 0.480 |
Why?
|
| Apolipoprotein E4 | 9 | 2015 | 57 | 0.470 |
Why?
|
| Hypoglycemic Agents | 6 | 2015 | 180 | 0.450 |
Why?
|
| Aging | 5 | 2013 | 938 | 0.430 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 2285 | 0.430 |
Why?
|
| Dementia | 6 | 2020 | 245 | 0.420 |
Why?
|
| Sleep | 5 | 2019 | 89 | 0.380 |
Why?
|
| Osteoarthritis | 4 | 2014 | 79 | 0.380 |
Why?
|
| Glucose Intolerance | 2 | 2010 | 46 | 0.370 |
Why?
|
| Estrogens | 2 | 2011 | 169 | 0.370 |
Why?
|
| Diet, Fat-Restricted | 1 | 2012 | 31 | 0.360 |
Why?
|
| Hydrocortisone | 1 | 2011 | 57 | 0.350 |
Why?
|
| Executive Function | 5 | 2019 | 56 | 0.330 |
Why?
|
| Prediabetic State | 1 | 2010 | 72 | 0.310 |
Why?
|
| Physical Fitness | 2 | 2010 | 133 | 0.310 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 126 | 0.310 |
Why?
|
| Motor Activity | 1 | 2012 | 327 | 0.300 |
Why?
|
| Lipid Metabolism | 3 | 2015 | 105 | 0.300 |
Why?
|
| Overweight | 4 | 2018 | 263 | 0.270 |
Why?
|
| Time Factors | 7 | 2019 | 2183 | 0.260 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2011 | 195 | 0.260 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2012 | 83 | 0.250 |
Why?
|
| Treatment Outcome | 15 | 2019 | 3441 | 0.250 |
Why?
|
| Hormone Replacement Therapy | 2 | 2017 | 89 | 0.240 |
Why?
|
| Affect | 3 | 2012 | 70 | 0.200 |
Why?
|
| Residence Characteristics | 2 | 2015 | 197 | 0.180 |
Why?
|
| Caloric Restriction | 2 | 2019 | 101 | 0.170 |
Why?
|
| Longitudinal Studies | 7 | 2019 | 779 | 0.170 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 136 | 0.170 |
Why?
|
| Analysis of Variance | 5 | 2015 | 459 | 0.170 |
Why?
|
| Sulfonamides | 3 | 2011 | 67 | 0.170 |
Why?
|
| Obesity | 5 | 2019 | 1152 | 0.170 |
Why?
|
| Diet | 2 | 2013 | 390 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 69 | 0.160 |
Why?
|
| Problem Solving | 2 | 2018 | 26 | 0.160 |
Why?
|
| Risk Factors | 4 | 2018 | 3976 | 0.160 |
Why?
|
| Genotype | 5 | 2013 | 731 | 0.160 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 4 | 0.150 |
Why?
|
| Amnesia | 2 | 2011 | 8 | 0.150 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 22 | 0.150 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2017 | 138 | 0.150 |
Why?
|
| Colorectal Surgery | 1 | 2018 | 2 | 0.150 |
Why?
|
| Cohort Studies | 7 | 2018 | 1844 | 0.140 |
Why?
|
| Research Design | 3 | 2020 | 332 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 24 | 0.140 |
Why?
|
| Interferon-gamma | 1 | 2018 | 59 | 0.140 |
Why?
|
| Heart Rate | 2 | 2010 | 343 | 0.140 |
Why?
|
| Dietary Fats | 2 | 2015 | 109 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 154 | 0.130 |
Why?
|
| Nootropic Agents | 1 | 2017 | 13 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 532 | 0.130 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 125 | 0.120 |
Why?
|
| Decision Making | 1 | 2018 | 202 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3705 | 0.120 |
Why?
|
| West Nile virus | 1 | 2016 | 2 | 0.120 |
Why?
|
| West Nile Fever | 1 | 2016 | 2 | 0.120 |
Why?
|
| Glucose Tolerance Test | 2 | 2015 | 125 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 222 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2017 | 103 | 0.120 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 167 | 0.120 |
Why?
|
| Apolipoproteins E | 5 | 2014 | 87 | 0.120 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 388 | 0.120 |
Why?
|
| Polysomnography | 1 | 2016 | 40 | 0.120 |
Why?
|
| Memory Disorders | 2 | 2008 | 54 | 0.120 |
Why?
|
| Retinal Diseases | 1 | 2016 | 26 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 41 | 0.120 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 72 | 0.120 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2015 | 3 | 0.120 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 57 | 0.120 |
Why?
|
| Insulin, Long-Acting | 1 | 2015 | 3 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2015 | 47 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2018 | 877 | 0.110 |
Why?
|
| Pain | 2 | 2014 | 295 | 0.110 |
Why?
|
| Body Mass Index | 5 | 2019 | 908 | 0.110 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 40 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 44 | 0.110 |
Why?
|
| Cerebellar Diseases | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cerebellar Cortex | 1 | 2014 | 4 | 0.110 |
Why?
|
| Laminin | 1 | 2014 | 13 | 0.110 |
Why?
|
| Housing | 1 | 2015 | 65 | 0.110 |
Why?
|
| Amyloid | 1 | 2014 | 16 | 0.110 |
Why?
|
| Naproxen | 2 | 2011 | 7 | 0.110 |
Why?
|
| Cysts | 1 | 2014 | 17 | 0.110 |
Why?
|
| Primary Health Care | 2 | 2014 | 231 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 97 | 0.110 |
Why?
|
| Commerce | 1 | 2015 | 69 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 2013 | 172 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2011 | 68 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 622 | 0.100 |
Why?
|
| Fatigue | 1 | 2014 | 83 | 0.100 |
Why?
|
| Mental Status Schedule | 4 | 2017 | 22 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2011 | 51 | 0.100 |
Why?
|
| Exercise Test | 2 | 2016 | 223 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2018 | 828 | 0.100 |
Why?
|
| Arthralgia | 1 | 2013 | 32 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2018 | 1461 | 0.100 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 75 | 0.100 |
Why?
|
| Patient Selection | 1 | 2014 | 281 | 0.090 |
Why?
|
| Administration, Intranasal | 4 | 2015 | 31 | 0.090 |
Why?
|
| Psychotherapy, Group | 1 | 2012 | 16 | 0.090 |
Why?
|
| Mental Recall | 3 | 2015 | 51 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 128 | 0.090 |
Why?
|
| Prevalence | 4 | 2019 | 1002 | 0.090 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 23 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 20 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2012 | 881 | 0.090 |
Why?
|
| Neuropeptides | 1 | 2011 | 19 | 0.090 |
Why?
|
| Food, Formulated | 1 | 2011 | 12 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 23 | 0.090 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 26 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2013 | 239 | 0.090 |
Why?
|
| Energy Metabolism | 2 | 2010 | 155 | 0.080 |
Why?
|
| Body Composition | 1 | 2012 | 388 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 98 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2014 | 862 | 0.080 |
Why?
|
| Thromboxane B2 | 1 | 2010 | 6 | 0.080 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2010 | 3 | 0.080 |
Why?
|
| Glucose Clamp Technique | 1 | 2010 | 12 | 0.080 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 32 | 0.080 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 37 | 0.080 |
Why?
|
| Brain Chemistry | 2 | 2013 | 29 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 38 | 0.080 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 265 | 0.080 |
Why?
|
| tau Proteins | 3 | 2017 | 39 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 95 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 150 | 0.070 |
Why?
|
| Octreotide | 1 | 2009 | 5 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 73 | 0.070 |
Why?
|
| Gastrointestinal Agents | 1 | 2009 | 6 | 0.070 |
Why?
|
| Somatostatin | 1 | 2009 | 11 | 0.070 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 120 | 0.070 |
Why?
|
| Norepinephrine | 2 | 2006 | 75 | 0.070 |
Why?
|
| Verbal Behavior | 1 | 2008 | 9 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 146 | 0.070 |
Why?
|
| Administration, Cutaneous | 2 | 2011 | 115 | 0.070 |
Why?
|
| Cloprostenol | 1 | 2007 | 1 | 0.070 |
Why?
|
| Thiazines | 1 | 2007 | 1 | 0.070 |
Why?
|
| Exfoliation Syndrome | 1 | 2007 | 2 | 0.070 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2007 | 2 | 0.070 |
Why?
|
| Ocular Hypertension | 1 | 2007 | 9 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2007 | 13 | 0.070 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2007 | 22 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1572 | 0.070 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2007 | 41 | 0.070 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 60 | 0.060 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2006 | 18 | 0.060 |
Why?
|
| Organ Size | 2 | 2017 | 219 | 0.060 |
Why?
|
| Hyperinsulinism | 1 | 2005 | 13 | 0.060 |
Why?
|
| Health Status | 2 | 2019 | 402 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2005 | 45 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2019 | 288 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2018 | 2329 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2017 | 258 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2015 | 92 | 0.060 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2004 | 3 | 0.050 |
Why?
|
| Cytokines | 1 | 2005 | 247 | 0.050 |
Why?
|
| Aptitude | 1 | 2004 | 2 | 0.050 |
Why?
|
| Automobile Driving | 1 | 2004 | 26 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2003 | 7 | 0.050 |
Why?
|
| Smoking | 2 | 2019 | 531 | 0.050 |
Why?
|
| Alleles | 2 | 2014 | 253 | 0.050 |
Why?
|
| Triglycerides | 1 | 2004 | 228 | 0.050 |
Why?
|
| Adult | 5 | 2016 | 9569 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 271 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1140 | 0.050 |
Why?
|
| Inflammation | 1 | 2005 | 536 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 307 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2002 | 27 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 106 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2013 | 356 | 0.040 |
Why?
|
| United States | 3 | 2016 | 4109 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 1307 | 0.040 |
Why?
|
| Attention | 2 | 2014 | 82 | 0.040 |
Why?
|
| Verbal Learning | 1 | 2019 | 8 | 0.040 |
Why?
|
| Indians, North American | 1 | 2019 | 110 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 50 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1197 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 476 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 467 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 2734 | 0.030 |
Why?
|
| Synaptotagmins | 1 | 2018 | 1 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2018 | 2 | 0.030 |
Why?
|
| Animals | 4 | 2015 | 7570 | 0.030 |
Why?
|
| F2-Isoprostanes | 2 | 2010 | 20 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 289 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 123 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 576 | 0.030 |
Why?
|
| Exosomes | 1 | 2018 | 44 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2011 | 565 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2017 | 100 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 594 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 272 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 767 | 0.030 |
Why?
|
| Oximetry | 1 | 2016 | 31 | 0.030 |
Why?
|
| Social Support | 1 | 2017 | 183 | 0.030 |
Why?
|
| Housing for the Elderly | 1 | 2015 | 4 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2015 | 17 | 0.030 |
Why?
|
| Residential Facilities | 1 | 2015 | 4 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2015 | 11 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1239 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2015 | 30 | 0.030 |
Why?
|
| Financing, Government | 1 | 2015 | 10 | 0.030 |
Why?
|
| Ownership | 1 | 2015 | 15 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 37 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2015 | 40 | 0.030 |
Why?
|
| Psychomotor Disorders | 1 | 2015 | 4 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 169 | 0.030 |
Why?
|
| Space Perception | 1 | 2015 | 28 | 0.030 |
Why?
|
| Radiography | 1 | 2016 | 386 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 308 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 144 | 0.030 |
Why?
|
| Muscular Dystrophies | 1 | 2014 | 4 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2014 | 18 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2015 | 105 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 2512 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 27 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 135 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1545 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 247 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2014 | 81 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 453 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 134 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 563 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 35 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 457 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 253 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2013 | 37 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 87 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 126 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 783 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 216 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 28 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2006 | 494 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2012 | 91 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 888 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 32 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 360 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 16 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2011 | 20 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 38 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 1012 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 148 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 301 | 0.020 |
Why?
|
| North Carolina | 1 | 2015 | 1546 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 1282 | 0.020 |
Why?
|
| Aspirin | 1 | 2010 | 62 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 135 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 764 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2009 | 48 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 3640 | 0.020 |
Why?
|
| Child | 1 | 2014 | 2478 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2007 | 41 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 45 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 422 | 0.020 |
Why?
|
| Japan | 1 | 2006 | 19 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 79 | 0.010 |
Why?
|
| Prealbumin | 1 | 2005 | 9 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2005 | 32 | 0.010 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2006 | 108 | 0.010 |
Why?
|
| PPAR gamma | 1 | 2005 | 44 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2005 | 240 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 213 | 0.010 |
Why?
|
| Ketone Bodies | 1 | 2004 | 8 | 0.010 |
Why?
|
| Mental Competency | 1 | 2004 | 10 | 0.010 |
Why?
|
| Language | 1 | 2004 | 45 | 0.010 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2003 | 3 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 58 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 72 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2004 | 99 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 94 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 122 | 0.010 |
Why?
|
| Prostate | 1 | 2003 | 69 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2003 | 129 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 433 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 497 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2002 | 95 | 0.010 |
Why?
|